The new paradigm of hepatitis C therapy: integration of oral therapies into best practices-Reference-Cited by-同舟云学术

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices

Published:2013-10-07 Issue:11 Volume:20 Page:745-760
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Afdhal N. H.¹,Zeuzem S.²,Schooley R. T.³,Thomas D. L.⁴,Ward J. W.⁵,Litwin A. H.⁶,Razavi H.⁷,Castera L.⁸,Poynard T.⁹,Muir A.¹⁰,Mehta S. H.¹¹,Dee L.¹²,Graham C.¹³,Church D. R.¹⁴,Talal A. H.¹⁵,Sulkowski M. S.¹⁶,Jacobson I. M.¹⁷,

Affiliation:

1. Division of Gastroenterology and Hepatology Beth Israel Deaconess Medical Center Harvard Medical School Boston MA USA

2. Department of Medicine J.W. Goethe University Hospital Frankfurt Germany

3. Division of Infectious Diseases San Diego School of Medicine University of California La Jolla CA USA

4. Division of Infectious Diseases Johns Hopkins University School of Medicine Baltimore MD USA

5. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta GA USA

6. Departments of Medicine and Psychiatry and Behavioral Sciences Montefiore Medical Center Albert Einstein College of Medicine Bronx NY USA

7. Center for Disease Analysis Louisville CO USA

8. Service d'Hepatologie Hopital Beaujon Assistance Publique Hopitaux de Paris Clichy France

9. Service d'Hepatologie Groupe Hospitalier Pitie‐Salpetriere Paris France

10. Gastroenterology and Hepatology Research Group Duke Clinical Research Institute Durham NC USA

11. Department of Epidemiology Johns Hopkins Bloomberg School of Public Health Baltimore MD USA

12. Fair Pricing Coalition and AIDS Action Baltimore Baltimore MD USA

13. Division of Infectious Disease Beth Israel Deaconess Medical Center Boston MA USA

14. Massachusetts Department of Public Health Bureau of Infectious Disease Boston MA USA

15. Division of Gastroenterology and Hepatology Department of Internal Medicine University at Buffalo Buffalo NY USA

16. Department of Medicine Johns Hopkins University School of Medicine Baltimore MD USA

17. Division of Gastroenterology and Hepatology Weill Cornell Medical College New York NY USA

Funder

Boehringer Ingelheim

Roche Molecular Diagnostics

Vertex Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Idenix Pharmaceuticals

Janssen Research & Development

Janssen Therapeutics

Laboratory Corporation of America

Liver Institute for Education and Research

Novartis Pharmaceuticals Corporation

Quest Diagnostics

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.12173

Reference113 articles.

1. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

2. Boceprevir for Untreated Chronic HCV Genotype 1 Infection

3. Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

4. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

5. Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis B and C in Pakistan: is there hope for a better treatment?;International Journal of Surgery: Global Health;2023-07

2. Resource Management through Artificial Intelligence in Screening Programs—Key for the Successful Elimination of Hepatitis C;Diagnostics;2022-01-29

3. Risk of Non-Hodgkin's Lymphoma in HCV Patients in the United States Between 2013 and 2020: A Population-Based Study;Clinical Lymphoma Myeloma and Leukemia;2021-11

4. Prevalence of Hepatitis C Virus Infection Identified From Nontargeted Screening Among Adult Visitors in an Academic Appalachian Regional Emergency Department;Open Forum Infectious Diseases;2021-08-01

5. B-type natriuretic peptide (BNP) in HCV-positive Egyptian patients: the impact of HCV eradication on plasma BNP levels;Egyptian Liver Journal;2021-07-30